Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD)

Ignazio Grattagliano, Agostino Di Ciaula, Jacek Baj, Emilio Molina-Molina, Harshitha Shanmugam, Gabriella Garruti, David Q.H. Wang, Piero Portincasa

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent metabolic chronic liver diseases in developed countries and puts the populations at risk of progression to liver necro-inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. Mitochondrial dysfunction is involved in the onset of NAFLD and contributes to the progression from NAFLD to nonalcoholic steatohepatitis (NASH). Thus, liver mitochondria could become the target for treatments for improving liver function in NAFLD patients. This chapter describes the most important steps used for potential therapeutic interventions in NAFLD patients, discusses current options gathered from both experimental and clinical evidence, and presents some novel options for potentially improving mitochondrial function in NAFLD.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages201-246
Number of pages46
DOIs
StatePublished - 2021

Publication series

NameMethods in Molecular Biology
Volume2310
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029

Keywords

  • Fatty liver
  • Mitochondria
  • Nitrosative stress
  • Nonalcoholic fatty liver disease
  • Oxidative stress

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Fingerprint

Dive into the research topics of 'Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD)'. Together they form a unique fingerprint.

Cite this